[HTML][HTML] Small molecule agents targeting PD-1 checkpoint pathway for cancer immunotherapy: mechanisms of action and other considerations for their advanced …

PG Sasikumar, M Ramachandra - Frontiers in Immunology, 2022 - frontiersin.org
Pioneering success of antibodies targeting immune checkpoints such as programmed cell
death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) has …

[HTML][HTML] Small Molecule Agents Targeting PD-1 Checkpoint Pathway for Cancer Immunotherapy: Mechanisms of Action and Other Considerations for Their Advanced …

PG Sasikumar, M Ramachandra - Frontiers in Immunology, 2022 - ncbi.nlm.nih.gov
Pioneering success of antibodies targeting immune checkpoints such as programmed cell
death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) has …

Small Molecule Agents Targeting PD-1 Checkpoint Pathway for Cancer Immunotherapy: Mechanisms of Action and Other Considerations for Their Advanced …

PG Sasikumar, M Ramachandra - Development and Potential …, 2022 - books.google.com
Pioneering success of antibodies targeting immune checkpoints such as programmed cell
death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) has …

Small Molecule Agents Targeting PD-1 Checkpoint Pathway for Cancer Immunotherapy: Mechanisms of Action and Other Considerations for Their Advanced …

PG Sasikumar, M Ramachandra - Frontiers in …, 2022 - pubmed.ncbi.nlm.nih.gov
Pioneering success of antibodies targeting immune checkpoints such as programmed cell
death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) has …

Small Molecule Agents Targeting PD-1 Checkpoint Pathway for Cancer Immunotherapy: Mechanisms of Action and Other Considerations for Their Advanced …

PG Sasikumar, M Ramachandra - Frontiers in Immunology, 2022 - europepmc.org
Pioneering success of antibodies targeting immune checkpoints such as programmed cell
death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) has …